β-adrenolityki i kwas acetylosalicylowy w prewencji i terapii chorób układu sercowo-naczyniowego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2014
Słowa kluczowe:
nadciśnienie tętnicze, choroba wieńcowa, prewencja, β-adrenolityki, kwas acetylosalicylowy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Terapia pacjentów z chorobami układu sercowo-naczyniowego często wiąże się z przyjmowaniem przez nich dużej liczby leków. Nierzadko przyczyną braku osiągnięcia celu terapeutycznego jest niestosowanie się chorych do zaleceń, zarówno zmiany stylu życia, jak i konsekwentnej farmakoterapii. Szereg badań klinicznych wykazało skuteczność skojarzeń lekowych w jednej tabletce np. w obniżaniu ciśnienia tętniczego. Zgodnie z aktualnymi wytycznymi Europejskiego Towarzystwa Kardiologicznego w codziennej praktyce klinicznej można spotkać kilka scenariuszy klinicznych ze wskazaniami do jednoczesnego stosowania kwasu acetylosalicylowego i β-adrenolityku. W takich sytuacjach można rozważyć użycie gotowych połączeń dwóch substancji czynnych w jednej kapsułce. Być może pozwoli to uzyskać większy odsetek osób, które będą stosować się do zaleceń lekarskich, przełoży się na wzrost skuteczności w osiąganiu celów terapeutycznych i efektów klinicznych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Balsam , P., & Grabowski , M. (2014). β-adrenolityki i kwas acetylosalicylowy w prewencji i terapii chorób układu sercowo-naczyniowego . Medycyna Faktów , 7(1(22), 51-57. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2382
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Perk J., De Backer G., Gohlke H. et al.: [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)]. Giornale Italiano di Cardiologia 2013; 14(5):328-92.
2. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of Hypertension 2013; 31(10): 1925-38.
3. Task Force on the management of STseamiotESoC; Steg P.G., James S.K., Atar D. et al.: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012; 33(20): 2569-619.
4. Brogneaux C., Sprynger M., Magnee M., Lancellotti P.: [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. Revue Medicale de Liege 2012; 67(11): 560-5.
5. Hamm C.W., Bassand J.P., Agewall S. et al.: [ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)]. Giornale Italiano di Cardiologia 2012; 13(3): 171-228.
6. Mangiapane S., Busse R.: Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction: the reality of care revealed by claims data analysis. Deutsches Arzteblatt International 2011; 108(50): 856-62.
7. Rodriguez L.A., Cea-Soriano L., Martin-Merino E. et al.: Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ 2011; 343: d4094.
8. McMurray J.J., Adamopoulos S., Anker S.D. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012; 33(14): 1787-847.
9. Task Force Members; Montalescot G., Sechtem U., Achenbach S. et al.: 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013; 34(38): 2949-3003.
10. Collaborative overview of randomised trials of antiplatelet therapy – III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308(6923): 235-46.
11. Juul-Moller S., Edvardsson N., Jahnmatz B. et al.: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340(8833): 1421-5.
12. Task Force on the management of STseami; van de Werf F., Bax J., Betriu A. et al.: ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Revista Espanola de Cardiologia 2009; 62(3): 293, e1-47.
13. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34(28): 2159-219.
14. Heidbuchel H., Verhamme P., Alings M. et al.: EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur. Heart J. 2013; 34(27): 2094-106.
15. Claxton A.J., Cramer J., Pierce C.: A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001; 23(8): 1296-310.
16. Kumagai N., Onishi K., Hoshino K. et al.: Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. Clinical and Experimental Hypertension 2013; 35(5): 355-60.
17. Domino F.J.: Improving adherence to treatment for hypertension. American Family Physician 2005; 71(11): 2089-90.
18. Rose A.J., Berlowitz D.R., Orner M.B. et al.: Understanding uncontrolled hypertension: is it the patient or the provider? Journal of Clinical Hypertension 2007; 9(12): 937-43.
19. Feldman R.D., Zou G.Y., Vandervoort M.K. et al.: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53(4): 646-53.
20. Derosa G., Cicero A.F., Carbone A. et al.: Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur. J. Pharm. Sci. 2014; 51: 26-33.
21. Kannel W.B.: Risk stratification in hypertension: new insights from the Framingham Study. American Journal of Hypertension 2000; 13(1 Pt 2): 3S-10S.
22. Thomas F., Rudnichi A., Bacri A.M. et al.: Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001; 37(5): 1256-61.
23. Indian Polycap Study (TIPS); Yusuf S., Pais P., Afzal R. et al.: Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373(9672): 1341-51.
24. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013; 31(7): 1281-357.
25. Julius S., Palatini P., Kjeldsen S.E. et al.: Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. The American Journal of Cardiology 2012; 109(5): 685-92.
26. Palatini P., Reboldi G., Beilin L.J. et al.: Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. International Journal of Cardiology 2013; 168(2): 1490-5.
27. Cucherat M.: Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur. Heart J. 2007; 28(24): 3012-9.
28. Anthonio R.L., Brouwer J., Lechat P. et al.: Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]). The American Journal of Cardiology 1999; 83(8): 1286-9, A10.
29. Grosser N., Schroder H.: Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler. Thromb. Vasc. Biol. 2003; 23(8): 1345-51.
30. Taubert D., Berkels R., Grosser N. et al.: Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. British Journal of Pharmacology 2004; 143(1): 159-65.
31. Wu R., Lamontagne D., de Champlain J.: Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 2002; 105(3): 387-92.
32. Zanchetti A., Hansson L., Dahlof B. et al.: Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. Journal of Hypertension 2002; 20(11): 2301-7.
33. Avanzini F., Palumbo G., Alli C. et al.: Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)–Hypertension study. American Journal of Hypertension 2000; 13(6 Pt 1): 611-6.
34. Walker J., Robinson J., Stewart J. et al.: Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interactive Cardiovascular and Thoracic Surgery 2007; 6(4): 519-22.
35. Kelly J.P., Kaufman D.W., Jurgelon J.M. et al.: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348(9039): 1413-6.
36. de Abajo F.J., Garcia Rodriguez L.A.: Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric- coated formulations. BMC Clinical Pharmacology 2001; 1: 1.
37. Brzozowski T., Marlicz K., Bartnik W.: Choroby żołądka i dwunastnicy. W: Interna Szczeklika 2013 – Podręcznik chorób wewnętrznych. Gajewski P., Szczeklik A. (red.). Medycyna Praktyczna, Kraków 2013: 901-25.
2. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of Hypertension 2013; 31(10): 1925-38.
3. Task Force on the management of STseamiotESoC; Steg P.G., James S.K., Atar D. et al.: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012; 33(20): 2569-619.
4. Brogneaux C., Sprynger M., Magnee M., Lancellotti P.: [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. Revue Medicale de Liege 2012; 67(11): 560-5.
5. Hamm C.W., Bassand J.P., Agewall S. et al.: [ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)]. Giornale Italiano di Cardiologia 2012; 13(3): 171-228.
6. Mangiapane S., Busse R.: Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction: the reality of care revealed by claims data analysis. Deutsches Arzteblatt International 2011; 108(50): 856-62.
7. Rodriguez L.A., Cea-Soriano L., Martin-Merino E. et al.: Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ 2011; 343: d4094.
8. McMurray J.J., Adamopoulos S., Anker S.D. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012; 33(14): 1787-847.
9. Task Force Members; Montalescot G., Sechtem U., Achenbach S. et al.: 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013; 34(38): 2949-3003.
10. Collaborative overview of randomised trials of antiplatelet therapy – III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308(6923): 235-46.
11. Juul-Moller S., Edvardsson N., Jahnmatz B. et al.: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340(8833): 1421-5.
12. Task Force on the management of STseami; van de Werf F., Bax J., Betriu A. et al.: ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Revista Espanola de Cardiologia 2009; 62(3): 293, e1-47.
13. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34(28): 2159-219.
14. Heidbuchel H., Verhamme P., Alings M. et al.: EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur. Heart J. 2013; 34(27): 2094-106.
15. Claxton A.J., Cramer J., Pierce C.: A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001; 23(8): 1296-310.
16. Kumagai N., Onishi K., Hoshino K. et al.: Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. Clinical and Experimental Hypertension 2013; 35(5): 355-60.
17. Domino F.J.: Improving adherence to treatment for hypertension. American Family Physician 2005; 71(11): 2089-90.
18. Rose A.J., Berlowitz D.R., Orner M.B. et al.: Understanding uncontrolled hypertension: is it the patient or the provider? Journal of Clinical Hypertension 2007; 9(12): 937-43.
19. Feldman R.D., Zou G.Y., Vandervoort M.K. et al.: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53(4): 646-53.
20. Derosa G., Cicero A.F., Carbone A. et al.: Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur. J. Pharm. Sci. 2014; 51: 26-33.
21. Kannel W.B.: Risk stratification in hypertension: new insights from the Framingham Study. American Journal of Hypertension 2000; 13(1 Pt 2): 3S-10S.
22. Thomas F., Rudnichi A., Bacri A.M. et al.: Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001; 37(5): 1256-61.
23. Indian Polycap Study (TIPS); Yusuf S., Pais P., Afzal R. et al.: Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373(9672): 1341-51.
24. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013; 31(7): 1281-357.
25. Julius S., Palatini P., Kjeldsen S.E. et al.: Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. The American Journal of Cardiology 2012; 109(5): 685-92.
26. Palatini P., Reboldi G., Beilin L.J. et al.: Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. International Journal of Cardiology 2013; 168(2): 1490-5.
27. Cucherat M.: Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur. Heart J. 2007; 28(24): 3012-9.
28. Anthonio R.L., Brouwer J., Lechat P. et al.: Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]). The American Journal of Cardiology 1999; 83(8): 1286-9, A10.
29. Grosser N., Schroder H.: Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler. Thromb. Vasc. Biol. 2003; 23(8): 1345-51.
30. Taubert D., Berkels R., Grosser N. et al.: Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. British Journal of Pharmacology 2004; 143(1): 159-65.
31. Wu R., Lamontagne D., de Champlain J.: Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 2002; 105(3): 387-92.
32. Zanchetti A., Hansson L., Dahlof B. et al.: Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. Journal of Hypertension 2002; 20(11): 2301-7.
33. Avanzini F., Palumbo G., Alli C. et al.: Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)–Hypertension study. American Journal of Hypertension 2000; 13(6 Pt 1): 611-6.
34. Walker J., Robinson J., Stewart J. et al.: Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interactive Cardiovascular and Thoracic Surgery 2007; 6(4): 519-22.
35. Kelly J.P., Kaufman D.W., Jurgelon J.M. et al.: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348(9039): 1413-6.
36. de Abajo F.J., Garcia Rodriguez L.A.: Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric- coated formulations. BMC Clinical Pharmacology 2001; 1: 1.
37. Brzozowski T., Marlicz K., Bartnik W.: Choroby żołądka i dwunastnicy. W: Interna Szczeklika 2013 – Podręcznik chorób wewnętrznych. Gajewski P., Szczeklik A. (red.). Medycyna Praktyczna, Kraków 2013: 901-25.